Skip to main content

The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review

Abstract

Background

Amyotrophic lateral sclerosis (ALS) is a fatal, rapidly progressive neurodegenerative disease that mainly affects the motor system. A number of potentially neuroprotective and neurorestorative disease-modifying drugs are currently in clinical development. At present, the evaluation of a drug’s clinical efficacy in ALS is based on the ALS Functional Rating Scale Revised, motor tests and survival. However, these endpoints are general, variable and late-stage measures of the ALS disease process and thus require the long-term assessment of large cohorts. Hence, there is a need for more sensitive radiological biomarkers. Various sequences for magnetic resonance imaging (MRI) of the brain and spinal cord have may have value as surrogate biomarkers for use in future clinical trials. Here, we review the MRI findings in ALS, their clinical correlations, and their limitations and potential role as biomarkers.

Methods

The PubMed database was screened to identify studies using MRI in ALS. We included general MRI studies with a control group and an ALS group and longitudinal studies even if a control group was lacking.

Results

A total of 116 studies were analysed with MRI data and clinical correlations. The most disease-sensitive MRI patterns are in motor regions but the brain is more broadly affected.

Conclusion

Despite the existing MRI biomarkers, there is a need for large cohorts with long term MRI and clinical follow-up. MRI assessment could be improved by standardized MRI protocols with multicentre studies.

Peer Review reports

Background

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that mainly affects the motor system. At present, the only drug to have produced an increase in patient survival in a controlled clinical trial is riluzole [1]. The condition is always fatal; the median survival time after onset is 36 [2], although there are great individual variations [3]. Although ALS is a clinically recognizable condition (in terms of the pattern of progressive upper and lower motor neuron degeneration), the clinical presentation and progression are heterogeneous [4]. Moreover, there are now strong reasons for considering a broader aetiological and pathogenic spectrum [5]. This clinical heterogeneity is observed in other neurodegenerative diseases, such as Parkinson’s disease (PD). Nevertheless, it has been found that all PD patients display degeneration and iron overload of the substantia nigra, which might become a surrogate biomarker [6]. In ALS, iron overload in the motor cortex was confirmed [7] after being suspected in mouse models [8]. Ongoing drug trials in the field of neurodegenerative disease are mainly seeking to establish neuroprotection and neurorestoration. Since neuroprotection can never be unambiguously demonstrated in a given patient, the concept of disease-modifying drugs (with a slowing of the disease progression) has arisen. At present, the evaluation of a drug’s clinical efficacy in ALS is based on the ALS Functional Rating Scale Revised, motor tests, survival or a combination of these measures (such as the Combined Assessment of Function and Survival (CAFS)) [9, 10]. However, these endpoints are general, variable and late-stage measures of the ALS disease process and thus require the long-term assessment of large cohorts. These assessments are risky and expensive, which considerably limits the number of trials being conducted. A sensitive surrogate biomarker might help to (i) reduce the sample size in pilot studies, (ii) better define the sample size required in Phase III clinical trials (by comparison with clinical scales) and (iii) define endophenotypes for separate assessment in clinical trials.

Biomarkers are typically divided into “wet biomarkers” and “dry biomarkers”. Wet biomarkers are biological substances that are measured in a body fluid (such as whole blood, serum, plasma, saliva or cerebrospinal fluid (CSF)). “Dry biomarkers” are based on functional scales, task performance, electrophysiology or imaging. Magnetic resonance imaging is a widely available and non-invasive technique, which makes it an appropriate candidate for biomarkers. Although early reports stated that ALS starts in the spinal cord, the initial site of neurodegeneration has not been unambiguously identified; disease may start in the spinal cord, in the motor cortex or at both sites simultaneously [11, 12]. The development of radiological biomarkers in ALS is facilitated by the hypothesis that the pathological changes in ALS radiate out from the initial spinal and brain areas in which the most severe upper and lower motor neuron dysfunction respectively occur (from symptom onset onwards) with variability in the predominance of upper and lower motor neuron dysfunction [13]. The neurodegeneration then progresses along the motor neurons of the ventral horn of the spinal cord and into the corresponding areas of the motor cortex [13]. Despite this modelization, the pattern of onset and progression remains complex [13]. Hence, MRI of the spinal cord should be an early, sensitive marker of subtle degeneration-related changes. However, MRI of the spinal cord is complicated by a number of technical difficulties (relative to MRI of the brain). Firstly, the magnetic field is inhomogeneous because the spinal cord is close to bone, soft tissues and air. Secondly, the spine has a small cross-sectional dimension, which thus requires high-resolution data acquisition. Thirdly, the spine is subject to motion of the CSF [14] and physiological motion due to breathing [15].

Many different MRI techniques and sequences – including voxel-based morphometry (VBM), diffusion tensor imaging (DTI), magnetic resonance spectroscopy (MRS), iron-sensitive sequences (T2*, R2* and SWI) and functional MRI (fMRI) - are available for studying ALS-related changes in the brain or spinal cord. Hence, we reviewed the correlations between MRI findings and clinical scores in ALS, and sought to establish whether particular sequences may have value as surrogate biomarkers in this disease.

Methods

We searched the PubMed database with the following keywords: “ALS AND MRI OR amyotrophic lateral sclerosis AND magnetic resonance imaging”, “ALS AND VBM OR amyotrophic lateral sclerosis AND magnetic resonance imaging ”, “ALS AND MR spectroscopy OR amyotrophic lateral sclerosis AND magnetic resonance spectroscopy”, “amyotrophic lateral sclerosis AND diffusion tensor imaging OR ALS AND DTI”, “amyotrophic lateral sclerosis AND functional magnetic resonance imaging OR ALS AND fMRI”. There was no limitation on the publication date but only publications in French or English were considered. We included (i) general MRI studies with a control group and an ALS group and (ii) longitudinal follow-up studies (even if a control group was lacking). We excluded therapeutic trials articles, reviews, studies focused only on particular subgroups of ALS patients such as cognitive impairment, genetic mutations.

Results

A total of 1336 articles were identified using database searching, 651 were recorded after duplicates removal. 405 were excluded (not ALS, not MRI or, therapeutic clinical trials, not English or French, reviews) and 130 articles were finally excluded (studies focused only on particulars subgroups of patients, other MRI sequences or lacking of a control group). We analysed 116 articles.

Brain imaging

Structural magnetic resonance imaging (Table 1)

Table 1 The main results of volumetric studies

Three methods based on a three-dimensional, T1-weighted sequence have been applied to ALS: VBM, volume analysis and the measurement of cortical thickness. As a volume-based analysis, VBM involves the automatic segmentation of grey matter and inter-subject comparison of the local grey matter density [16, 17]. After all the data have been transformed in the same stereotaxic space, the images are partitioned and corrected for the separation between white matter, grey matter and CSF as a function of voxel intensity [17]. Measurement of cortical thickness is a surface-based technique analysis in which the white matter and pial surfaces are automatically extracted by applying image analysis packages such as Freesurfer (http://surfer.nmr.mgh.harvard.edu/).

Most of these techniques have evidenced atrophy in the precentral gyri [1832]. However, some DTI studies used VBM to show that ALS vs. control differences in the fractional anisotropy (FA) of the precentral gyri were not due to atrophy [33, 34]. In other studies, cortical atrophy was not limited to the precentral gyri but extended to other regions of the frontal lobe [1824, 2628, 32, 35] - especially in apathetic patients with involvement of the cingulate cortex [27, 36]. Other regions involved include several parts of the temporal cortex [1924, 32, 35], the hippocampus [24, 3739], the parietal cortex (mostly in the post-central cortex [18, 21, 23, 28]) and the insula [24]. Occipital grey matter atrophy [19, 20, 24, 35] and cerebellar atrophy were less common [24]. When considering the basal ganglia, a low volume of the thalamus [22, 24, 37] and the caudate nucleus [37] have been observed. Few studies have evidenced a relative reduction in the volume of white matter (mainly in the frontal and temporal lobes) [23]. There were no marked differences in the corpus callosum [40]. Whole-brain analyses have evidenced low volumes in the neocortex, grey matter, white matter [28] and brain parenchyma [28, 32]. A longitudinal study showed (i) a volume reduction in the left subiculum, the right hippocampal area CA4 and the right dentatus gyrus and (ii) an enlargement of the ventricles in 39 of the 112 ALS patients [38].

Clinical correlations

Specific MRI abnormalities have been correlated with clinical scores, the disease stage (as estimated with the original or revised ALS Functional Rating Scale (ALSFRS and ALSFRS-R, respectively), the speed of disease progression (i.e. the change in ALSFRS or ALSFRS-R score, divided by the disease duration or the time interval between two clinical assessments), the disease duration and the survival time. Lower ALSFRS or ALSFRS-R scores were associated with larger ventricles and greater volume loss in the basal ganglia [38], and volume changes in several parts of the frontal lobe (such as Brodman area 10) [18]. In another study, a higher ALSFRS-R progression rate was associated with MRI changes in the left sensorimotor area; cortical thickness was lower in patients with predominantly upper motor neuron impairment (especially in the precentral gyrus and the left paracentral lobule), whereas patients with predominantly lower motor neuron impairment showed less difference relative to controls [20]. Grey matter density was lower in the cingulate and right inferior frontal gyrus in patients with impaired emotional empathy [36]. Poor survival in ALS is correlated with volume loss in the basal ganglia and limbic structures [38]. The initial side of limb weakness in ALS patients was not correlated with contralateral brain cortical loss of volume [27]. Although atrophy was predominant in the left sensorimotor cortex [27, 28], it was not related to the side of onset [27]. A subgroup analysis (by side of onset) found more widespread atrophy in the contralateral brain cortex than in the group of ALS patients as a whole [28]. Precentral cortical thickness was lower in patients with upper motor neuron clinical features than in those with lower motor neuron clinical features and in the ALS group as a whole [29].

In a study with a post mortem T1 sequence and histological assessment, an abnormally small difference in intensity between cortical grey matter and subcortical white matter was observed not only in the motor cortex (including the precentral gyrus, supplemental motor area and premotor cortex) but also in somatosensory areas and the primary visual cortex. These signal abnormalities were linked to neuron loss and an elevated number of astrocytes [41].

Diffusion tensor imaging (Table 2)

Table 2 The main results of DTI studies

DTI (also known as magnetic resonance tractography) is based on the random diffusion (Brownian motion) of molecules. In a spherical volume, the diffusion of water has no main direction and its diffusion in the three directions (λ1, λ2 and λ3) is equally likely. However, this is no longer the case in an ellipsoid or cylindrical volume and the diffusion is anisotropic. λ1 is the volume’s main axis (axial diffusivity, AD) and λ2 and λ3 are the minor axes (radial diffusivity, RD). By analysing the diffusion of water in three directions, four parameters can be defined: FA, RD, AD and mean diffusivity (MD, which is the average of diffusion in the λ1, λ2 and λ3 axis, also referred to as the apparent diffusion coefficient (ADC)). The first three parameters describe the spatial variation of water movement and are related to the orientation of the studied structures. In contrast, MD corresponds to the mean displacement of the water molecules within the volume. The main application of DTI is the analysis of the anatomical bundles that compose the white matter of the brain and the spinal cord [4244]. Whereas DTI corresponds to the analysis of the above-mentioned parameters in a defined volume, tractography corresponds to the analysis of a complete white matter tract.

Fractional anisotropy in ALS

Low FA along entire corticospinal tracts (CSTs) is the most common observation in patients with ALS [34, 4558]. However, some studies have only reported low FA in one or several parts of a CST: the subcortical white matter of the precentral gyrus [23, 24, 30, 33, 5965], the corona radiata [24, 6062, 6668], the posterior limb of the internal capsule (PLIC) [24, 33, 60, 62, 63], the cerebral peduncles [21, 59, 61] and the pons [61]. Lastly, only one study failed to observe a difference in FA along a CST in ALS patients by region of interest approach whereas tract based spatial statistics (TBSS) showed decreased FA in corona radiate and corpus callosum [68].

Low FA has also been observed in other regions: the frontal lobe (excluding the CST) [21, 24, 33, 34, 45, 52, 56, 57, 61, 64], the cingulum [60], the corpus callosum [21, 33, 45, 50, 52, 58, 61, 6769], the parietal lobe [24, 34, 45], the temporal lobe [21], parahippocampal areas [61], the hippocampus [34], the insula [34, 52], the cerebellum [61] and the thalamus [24, 33, 53]. In a whole-brain comparison, many other small areas of ALS-modified white matter tracts were observed [70].

A tractography study revealed that the CST volumes of ALS patients are lower than in controls [71]. A DTI study using a tract of interest-based fibre tracking found that the radiological results mirrored the neuropathological staging system [72], suggesting that the disease process extended in the following sequence: the corticospinal tract (stage 1), the corticorubral and corticopontine tracts (stage 2), the corticostriatal tract (stage 3) and the proximal portion of the perforant pathway (stage 4) [73]. The researchers suggested that this MRI-based staging system could be used as a surrogate marker of disease progression in clinical studies of ALS.

Diffusivity in ALS

The most common observation in patients with ALS is a relative increase in MD, reflecting changes in white matter tracts. The MD was elevated along entire CSTs [51, 53, 69] and in parts of CSTs, including subcortical white matter in the precentral gyrus [23, 34, 58, 60, 61], the corona radiata [34, 60], the PLIC [23, 34, 60, 74], the cerebral peduncles and the pons [34]. Diffusivity was also elevated in several parts of the frontal lobe [23, 24, 52, 58, 60, 61], the temporal lobe [23, 24, 52, 61], the hippocampal region [24, 34, 52], the parahippocampal region [60], the parietal lobe [23, 58, 61], the insula [23, 24, 52], the cingulum [53, 60], the occipital lobe [23], the cerebellum [23, 60] (especially in C9ORF72-positive patients) [75], the corpus callosum [23, 52, 60, 69] and the thalamus [53]. Conversely, two studies did not detect any differences in diffusivity in ALS patients vs. controls [21, 63].

Radial and axial diffusivity in ALS

Several studies have found elevated RD and AD values in the right CST, the right cingulum and the left anterior thalamic radiations (on the basis of changes in FA or MD) [53]. In the PLIC, AD is low [63] and RD is elevated [67] - especially in patients presenting with T2 hyperintensities in CSTs [63]. RD is elevated in white matter connected to the primary motor cortex, the premotor cortex [56] and the corpus callosum [56, 67, 69]. Lastly, RD and AD are elevated in the cerebellum of C9ORF72-positive patients [75].

Longitudinal studies

In longitudinal analyses, low FA is observed in the right superior CST [62], precentral subcortical regions, mesencephalic CSTs and parts of cerebellum [61]. FA was found to fall in a progressive, linear manner along the CSTs [34, 46, 76], and the diffusivity of the external and internal capsule was elevated [61]. AD is elevated in CSTs [77]. However, a recent longitudinal study found that white matter defects (as assessed by DTI) progressed much slowly that in the grey matter defects - notably in the basal ganglia [78].

Clinical correlations

Many studies have found that disease progression (as defined by the change over time in the ALSFRS or ALSFRS-R score) is correlated with the changes in FA in CSTs [24, 34, 45, 61, 62, 77, 79]. Furthermore, the disease duration is correlated with FA in entire CSTs or parts of CSTs [24, 50, 54, 56, 61, 77]. Conversely, the disease duration was negatively correlated with FA in the cerebellum [61], the subcortical white matter of insula, the ventrolateral premotor cortex, the cingulum, the precuneus and the splenium of the corpus callosum [24]. Lower-limb muscle strength was correlated with the contralateral FA in CSTs [60]. Diffusivity values in CSTs and in the parietal lobe, temporal lobe and cerebellum were also correlated with disease progression [52, 79]. Diffusivity in CSTs was correlated with disease duration [79], and contralateral diffusivity in CSTs was correlated with spasticity [59].

Whereas both limb-onset patients and bulbar-onset patients differed from controls in terms of FA along CSTs, the two patient groups had similar values [60]. The CSTs were more impaired in bulbar-onset patients than in limb-onset patients when considering FA, MD and RD but not AD [80]. Tractography revealed a large number of differences between controls and patients defined as definite/probable according to the El Escorial criteria, whereas there were fewer differences between controls and a possible/suspected group [79].

Neurophysiological correlations

FA in CSTs was related to the central conduction time in a transcranial magnetic stimulation study [33, 49] (Iwata et al., [49]; Sach et al., [33]).

Diagnostic accuracy

An individual patient data meta-analysis of CST studies concluded that DTI lacks sufficient diagnostic discrimination [81]. The pooled sensitivity and specificity were only 0.68 and 0.73, respectively. Researchers have also suggested that a multimodal approach (combining DTI with methods such as MRS) may be more promising [55].

Magnetic resonance spectroscopy (Table 3)

Table 3 main results of magnetic resonance spectroscopy studies

MRS is a non-invasive means of assessing brain metabolism, based on the chemical properties of molecular structures. Results are expressed as peaks. The main brain metabolites monitored with MRS include N-acetyl-aspartate (NAA), choline (Cho, a cell membrane marker), creatine (Cr) and phosphocreatine (Pcr). The Cr + Pcr peak is a marker of energy metabolism; the level of Cr is assumed to be stable and is used to calculate the metabolite ratio. At a field strength of 1.5 T, the peaks for glutamine (Gln), glutamate (Glu, an excitatory neurotransmitter) and gamma aminobutyric acid (GABA, an inhibitory neurotransmitter) overlap to form a complex referred to as “Glx”; higher field strengths are required for more accurate quantification of this metabolites. The simple sugar myo-inositol (Ins) is absent from neurons but present in glial cells. Hence, elevated brain levels of Ins are associated with glial proliferation, whereas low levels are associated with glial destruction [8284].

The main results for the CST concern the ratio between the NAA peak on one hand and the Cho and Cr + Pcr peaks on the other. In ALS patients, low levels of NAA have been observed in the precentral corticosubcortical region [8591], in the PLIC [85] and in entire CSTs [55, 59, 86, 92]. Glu and Glu + Gln were found to be elevated in the precentral corticosubcortical region and in the PLIC [85], whereas Cho was found to be elevated in the precentral region [88, 93, 94] and along the CSTs [47, 59, 92]. Levels of the inhibitory neurotransmitter GABA were low in the precentral cortex [55, 95], and levels of Ins were low in the precentral corticosubcortical region [89].

Whereas the above-mentioned studies used defined voxels for MRS acquisition, whole-brain spectroscopy has revealed low NAA/Cho or NAA/Cr ratios in many other regions [93].

Follow-up studies have shown a decrease in the NAA peak in the precentral cortex (with no differences for other metabolites) [96], a decrease in the NAA/Cho peak and an increase in the Cho/Cr peak [91].

Clinical correlations

Patients with definite or probable ALS (according to the El Escorial criteria) had low levels of NAA and high levels of Ins and Cho in the precentral cortex. In patients with possible or suspected ALS, only Cho and (on the left side) Ins were elevated. In another study of suspected ALS patients, only right-side Ins and right-side Cho were elevated [79]. Low NAA and high Cho and Ins levels are associated with clinical disease severity [94]. Lower NAA levels in the precentral gyrus, disease duration and disease progression were intercorrelated [59], and a low NAA/Cho ratio was associated with poor survival [88].

Diagnostic accuracy

In a recent study, the combination of MRS and DTI yielded a sensitivity of 0.93 and a specificity of 0.85, whereas the DTI data alone gave values of 0.86 and 0.70, respectively [55]. A criterion combining the MRS data, hypointensity in the precentral gyri and hyperintensity in the CSTs yielded a sensitivity of 0.78 and a specificity of 0.82; when each of the three parameters was considered alone, the sensitivity and specificity values did not exceed 0.71 and 0.75, respectively [90].

Iron imaging

Iron overload appears to be involved in the physiopathology of ALS [8, 97]. However, very few studies have analysed the iron content in the brain of ALS patients. A variety of techniques are available, including relaxometry (T2, T2* or R2*) and the susceptibility-weighted imaging [98, 99] (SWI, which is probably more sensitive than relaxometry [100]). Multi-echo T2* and R2* sequences are sensitive to magnetic field inhomogeneities. The value of R2* is measured by voxel-by-voxel modelling of the exponential decrease in signal [101, 102]. In post-mortem studies, R2* values have been found to be correlated with the iron content [103].

Susceptibility-weighted imaging and quantitative susceptibility mapping (QSM)

SWI is derived from T2* sequences and can be described as a flow-compensated, high-spatial-resolution T2* weighted sequence. The main advantage over conventional T2* sequence is better contrast [101]. QSM is based on the analysis of phase information. The main sources of phase shifts in biological tissues are the iron, calcium, lipid and myelin contents [104]. The value of QSM in ALS was confirmed in a post-mortem study, in which the iron content of grey matter was assessed more accurately than that of white matter [105].

The initial studies in the field noted a shorter T2 time in the motor cortex of most ALS patients (vs. controls) [106], although this was not confirmed a few years later [107]. Later studies found a correlation being T2* shortening and iron deposition in the microglia of the motor cortex (according to a post-mortem examination) [7, 106, 108]. Iron overload in the motor cortex was also described in SWI studies [109] and qualitative studies [100]; in the later study, there were no differences between ALS patients and controls in terms of T2 or T2*. A few quantitative studies have looked at white matter or deep grey matter [109, 110]. There was a trend towards iron accumulation in CST white matter in a relaxometry study [110]. Iron overload was also present in the red nucleus, substantia nigra, globus pallidus, putamen [109] and caudate nucleus [110]. The use of SWI sequences revealed widespread iron overload and myelin defects in the white matter of all brain lobes and corpus callosum [111]. A retrospective study of iron deposition in motor cortex found that quantitative susceptibility mapping was more accurate than T2*, T2 or FLAIR sequences [112].

A follow-up study has highlighted the progression of a T2 hypointense area in the motor cortex after 6 months, which was strongly and negative correlated with the ALSFRS score [108]. Lastly, changes in SWI sequences in the corpus callosum are correlated with the ALSFRS-R score [111].

Imaging of the spinal cord

The few studies to have analysed the spinal cord revealed atrophy in the cervical and upper thoracic regions [113115]. A DTI study reported low FA, elevated RD and a high magnetization transfer ratio in lateral segments of the cervical spinal cord [114]. Atrophy of the cervical and upper thoracic spinal cord progressed over time, whereas the DTI changes were relatively stable [115]. This observation agrees with the results of a longitudinal brain MRI study showing that grey matter defects (but not white matter defects) progressed over time [78]. Sensory pathways were also involved, with a decreased FA and an elevated MD and elevated RD in the posterior part of the cervical spinal cord [115, 116]. MRS of the cervical spinal cord revealed low NAA/Cr + Pcr and NAA/Ins peaks and an elevated Ins/Cr peak [117].

Clinical correlations

Cervical and upper thoracic spinal cord atrophy was correlated with upper arm muscle strength, as measured by manual testing [114]. FA in the cervical spinal cord was correlated with the ALSFRS score. The rate of atrophy in a follow-up study was correlated with the rates of changes of an arm ALSFRS-R score and an arm strength score (in a manual test) [115]. The NAA/Cr + Pcr and NAA/Ins peaks were positively correlated with the ALSFRS-R score and forced vital capacity but negatively correlated with disease progression [117].

Functional MRI

Brain fMRI is a recent technique based on blood flow and blood-oxygen-level dependent (BOLD) contrast, which in turn are based on the neurovascular consequences of neuronal activation [118]. The paramagnetic properties of deoxyhaemoglobin lead to signal reduction in gradient echo sequences [101]. Brain fMRI sequences are acquired in the resting state or during performance of a motor, auditory, cognitive, or visual task [119121]. The resting state sequences are quite similar to T2* sequences [101].

In the resting state, functional connectivity is based on fluctuations of the BOLD signal. In general, seven “default” networks can be identified: default mode, executive control, visual salience, sensorimotor, dorsal attention and auditory networks [118, 122]. Functional connectivity between specific brain regions and/or networks and the rest of the brain can then be analysed [118]. Resting-state analysis can also provide information about local activation (by analysing the amplitude of low-frequency fluctuations (ALFF), for example).

The resting state

Resting-state studies have evidenced the widespread reorganization of functional connectivity in ALS patients. This reorganization can be observed as either elevated functional connectivity or low functional connectivity. Functional connectivity was found to be low in several parts of the frontal lobe (the right orbitofrontal cortex, the left inferior frontal cortex [123] and especially the motor cortex [124]) but was elevated in the parietal lobe (the left precuneus and the right angular gyrus [123]) and the left frontoparietal network [123]. This agrees with the elevated sensorimotor connectivity of the left sensorimotor cortex with several regions of the right hemisphere (mainly the cingulate cortex, parahippocampal gyrus and cerebellum crus II) [125]. When compared with alterations of the CSTs (according to FA measurements), there were also changes in right sensorimotor connectivity; the connectivity was elevated if the CST was normal in a DTI analysis but was low if the CST was abnormal [125]. A network-by-network analysis revealed low activity in the default mode network [126] and elevated activity in the sensorimotor network (both of which include parts of the frontal lobe [126, 127], although not the same ones). Thalamic connectivity is also elevated [127].

Resting-state activity (as measured by the ALFF) was elevated in the frontal lobe (the left anterior cingulate, right superior frontal cortex [31] left medial frontal gyrus and right inferior frontal gyrus [128]), the temporal lobe (the right parahippocampal cortex and the left inferior temporal cortex) and the occipital lobe (the middle occipital cortex) [31] but low in the right fusiform gyrus, the visual cortex and right postcentral gyrus [128].

The resting-state connectivity in the frontal cortex is correlated with disease progression and duration [128]. The connectivity between the left sensorimotor cortex and the right parahippocampal gyri and fourth cerebellar lobule is correlated with the ALSFRS-R [125]. Connectivity of the dorsal part of the precentral gyri was correlated with hand strength [124]. Activity in the right parahippocampal gyri was correlated with disease progression, whereas activity in the left anterior cingulate and left temporal gyrus was correlated with cognitive parameters [31].

Activation in fMRI

In motor tasks, activation of the motor cortex was elevated [129131] and spread widely across the supplementary motor area, the premotor cortex [132] and the parietal somatosensory cortex [129, 132]. Inhibition was low [130]. Activation of the ipsilateral sensorimotor cortex was possibly linked to a compensatory mechanism in ALS [133]. A visual task was associated with poor activation of the secondary visual cortex and strong activation of associative areas, whereas an auditory task produced delayed activation in the secondary auditory cortex, and somatosensory stimulation produced prolonged activation of the right inferior frontal gyrus and right posterior insular cortex [134]. In a modified “go”/“no-go” task, activation of the primary motor cortex, other motor areas, the frontal lobe, the insula and the cerebellum was found to decrease over a three-month period [135]. Using another type of stimulus, activation of the hippocampus also fell after 3 months [135]. In a theory-of-mind task designed to evaluation the mirror neuron system, ALS patients displayed abnormally strong activation of the right anterior cortical areas [136]. A link between the severity of motor weakness and the pattern of activation has never been observed, although the ALSFRS-R score was correlated with the signal change in the sensorimotor cortex in one study [129]. When considering the clinical phenotype, only a bulbar-onset subgroup showed low activation of the motor cortex during tongue movements [131]. Shifts in cerebellar or hippocampal activation were correlated with the ALSFRS-R score.

Discussion

When considering the data as a whole, the most disease-sensitive MRI patterns are located in motor regions (and especially along the CST from the cortex to the spinal cord). However, ALS also affects the brain more broadly; other parts of the frontal lobe, the temporal lobe, the hippocampus, the parietal lobe, the cingulum and the insula are commonly involved, whereas the occipital lobe is less frequently involved. For most MRI parameters, patient vs. control differences are mostly apparent in the left (dominant) hemisphere. The various MRI patterns appear to reflect disease severity, progression and duration. With fMRI, abnormally high levels of activation in the motor cortex are probably related to the disease-related loss of inhibition. Excessive activation appears to be associated with compensation for the loss of function caused by neuron loss.

Limitations of neuroimaging as a biomarker for ALS

The low average number of participants represents the main limitation: very few published studies have featured more than 30 subjects per group (i.e. ALS and control groups). Together with the differences in the proportions of the various patient phenotypes, this explains the high variability of the results - particularly outside the motor cortex and the CSTs [137].

Only a small proportion of morphometric studies included a whole-brain analysis. The proportion is higher for DTI studies and low (only one study) for MRS. The selection of regions of interest may over-emphasize changes in the CSTs and the motor system and under-emphasize changes outside these areas.

Very few studies had a longitudinal design, which is nevertheless required for the full interpretation of abnormalities. The main difficulty in setting up longitudinal studies relates to the rapid disease progression and the appearance of respiratory failure, which prevents patients from lying in the MRI for any length of time. In studies longer than 6 months, the drop-out rate is usually over 50 %.

fMRI studies have highlighted both elevated activity and low activity in several parts of the brain. The main physiopathological explanations relate to a physiological compensation response or elevated activity due to the loss of inhibitory mechanisms [127].

Spinal cord imaging is a rarely applied imaging modality in ALS, despite the pivotal involvement of the anterior horn of the spinal cord in ALS [137]. Spinal cord imaging appears to be most commonly used in studies of multiple sclerosis, since all studies in this disease context found differences (relative to controls) in the cervical spinal cord. To the best of our knowledge, no studies of the whole spinal cord have been published – perhaps as a result of technical obstacles.

The biomarker concept

Currently, the diagnosis of ALS is based on the revised El Escorial criteria (also known as the Airlie House criteria), which were established in 1998 and published in 2000 [138]. Although diagnosis during the course of the disease has become relatively easy, the onset of ALS can be masked by clinical overlap with many other diseases [139]. The ideal biomarker is not only sensitive and specific (for various disease phenotypes) early in the disease process but must also easy to access [140]. In ALS, the typical time interval of 12 months between the initial symptoms and disease diagnosis makes this challenge tougher still [140142]. The best way of determining early biomarkers for ALS may be to monitor cohorts of presymptomatic patients identified by genetic studies [143]. Although wet biomarkers based on blood or CSF analysis are relatively accessible, there are many candidates and study-to-study reproducibility appears to be quite low [5, 140].

Perspectives

There is currently a need for a robust clinical-radiological description of ALS using MRI as a function of the disease progression, the various endophenotypes and left/right asymmetry (in terms of upper and lower motor neuron impairment, bulbar involvement, and the cognitive profile ranging from frontotemporal dementia, apathy and dysexecutive syndrome to mild attention disorders).

Despite the few number of studies, spinal cord could be a promising region of interest, although this approach is currently limited by technical post-processing difficulties and a sizeable number of large scale and longitudinal studies involving the spinal cord is needed to build stronger MRI biomarkers of the spinal cord. It may be of value to combine several techniques (e.g. atrophy mapping and measurements of the iron content in the grey matter). The results of MRI of the spinal cord are well correlated with the clinical impairment and might be a good surrogate marker.

A comprehensive analysis of MRI parameters in very large cohorts of ALS patients might reveal a radiological surrogate marker for use in clinical trials. Several points should be considered for large scale studies: in 2010, the first Neuroimaging Symposium in ALS (NiALS) had the aim of establishing consensus about the various applications of MRI to the study of ALS and the possibility of multicentre collaboration. Consensus criteria for the main MRI sequences (VBM, DTI, fMRI and spectroscopy) and the main clinical dataset were established [144]. The aim of this consensus was to lead large multicentre and longitudinal studies in imaging research or therapeutic trials [144]. <In our days, studies might better assess the most recent discovers in ALS such as genetic parameters (especially C9ORF72 expansion), the knowledge in cognitive and behavioural impairments even if the patients do not fulfil criteria for frontotemporal dementia [145]. There is still a need for longitudinal studies especially in presymptomatic and early phase of the disease [145]. Following this multicentre aim, a very recent study showed in 253 patients and 189 controls from eight international ALS specialised centre more widespread white matter tract change pooling the analyses than in single-centre analysis and reached estimation of neuropathological changes [146].

Conclusion

The MRI biomarkers appear to be well correlated with disease severity, duration and progression and are more sensitive in the brain and spinal cord motor regions. The built of MRI biomarkers is limited by the clinical various phenotypes but also by the lack of large and longitudinal studies. To date large cohorts with multicentre studies using a standardized MRI protocol are needed.

Abbreviations

AD:

Axial diffusivity

ADC:

Apparent diffusion coefficient

ALFF:

Amplitude of low frequency fluctuations

ALS:

Amyotrophic lateral sclerosis

ALSFRS:

Amyotrophic lateral sclerosis functional rating scale

ALSFRS-R:

Amyotrophic lateral sclerosis functional rating scale revised

CAFS:

Combined assessment of function and survival

Cho:

Choline

Cr:

Creatine

CSF:

Cerebro spinal fluid

CST(s):

Cortico-spinal tract(s)

DTI:

Diffusion tensor imaging

FA:

Fractional anisotropy

fMRI:

Functional magnetic resonance imaging

GABA:

Gamma aminobutyric acid

Gln:

Glutamine

Glu:

Glutamate

Glx:

Glutamine and glutamate

Ins:

myo-inositol

MD:

Mean diffusivity

MRI:

Magnetic resonance imaging

MRS:

Magnetic resonance spectroscopy

NAA:

N-acetyl-aspartate

NiALS:

Neurimaging symposium in amyotrophic lateral sclerosis

Pcr:

Phosphocreatine

PD:

Parkinson’s disease

PLIC:

Posterior limb of internal capsule

QSM:

Quantitative susceptibility mapping

RD:

Radial diffusivity

SWI:

Susceptibility weighted imaging

VBM:

Voxel-based morphometry

References

  1. 1.

    Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585–91.

    CAS  PubMed  Google Scholar 

  2. 2.

    Soriani M-H, Desnuelle C. Épidémiologie de la SLA. Rev Neurol (Paris). 2009;165(8–9):627–40.

    Google Scholar 

  3. 3.

    Beghi E, Logroscino G, Chiò A, Hardiman O, Mitchell D, Swingler R, et al. The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2006;1762(11–12):1150–7.

    CAS  Google Scholar 

  4. 4.

    Mitchell JD, Borasio GD. Amyotrophic lateral sclerosis. Lancet. 2007;369(9578):2031–41.

    CAS  PubMed  Google Scholar 

  5. 5.

    Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, Mcgrath M, et al. Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2013;14(S1):19–32.

    Google Scholar 

  6. 6.

    Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting Chelatable Iron as a Therapeutic Modality in Parkinson’s Disease. Antioxid Redox Signal. 2014;21(2):195–210.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Kwan JY, Jeong SY, Van Gelderen P, Deng H-X, Quezado MM, Danielian LE, et al. Iron Accumulation in Deep Cortical Layers Accounts for MRI Signal Abnormalities in ALS: Correlating 7 Tesla MRI and Pathology. Ashizawa T, editor. PLoS ONE. 2012 Apr 17;7(4):e35241.

  8. 8.

    Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, David S. Dysregulation of Iron Homeostasis in the CNS Contributes to Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis. J Neurosci. 2009;29(3):610–9.

    CAS  PubMed  Google Scholar 

  9. 9.

    Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: A useful predictor for ALS-progression. J Neurol Sci. 2008;275(1–2):69–73.

    PubMed  Google Scholar 

  10. 10.

    Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: Subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Front Degener. 2013;14(1):44–51.

    CAS  Google Scholar 

  11. 11.

    Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Tredici KD. Amyotrophic lateral sclerosis—a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9(12):708–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 12.

    The ALS Schwaben Register Group, Rosenbohm A, Kassubek J, Weydt P, Marroquin N, Volk AE, et al. Can lesions to the motor cortex induce amyotrophic lateral sclerosis? J Neurol. 2014;261(2):283–90.

    Google Scholar 

  13. 13.

    Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread Deconstructing motor neuron degeneration. Neurology. 2009;73(10):805–11.

    PubMed  PubMed Central  Google Scholar 

  14. 14.

    Stroman PW, Wheeler-Kingshott C, Bacon M, Schwab JM, Bosma R, Brooks J, et al. The current state-of-the-art of spinal cord imaging: Methods. Neuroimage. 2014;84:1070–81.

    CAS  PubMed  Google Scholar 

  15. 15.

    Verma T, Cohen-Adad J. Effect of respiration on the B 0 field in the human spinal cord at 3T: Effect of Respiration on B 0 Field in Human Spinal Cord. Magn Reson Med. 2014;72(6):1629–36.

    PubMed  Google Scholar 

  16. 16.

    Bandettini PA. What’s New in Neuroimaging Methods? Ann N Y Acad Sci. 2009;1156(1):260–93.

    PubMed  PubMed Central  Google Scholar 

  17. 17.

    Ashburner J, Friston KJ. Voxel-based morphometry--the methods. Neuroimage. 2000;11(6 Pt 1):805–21.

    CAS  PubMed  Google Scholar 

  18. 18.

    Grosskreutz J, Kaufmann J, Frädrich J, Dengler R, Heinze H-J, Peschel T. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol. 2006;6(1):17.

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Mezzapesa DM, Ceccarelli A, Dicuonzo F, Carella A, De Caro MF, Lopez M, et al. Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. 2007;28(2):255–9.

    CAS  PubMed  Google Scholar 

  20. 20.

    Mezzapesa DM, D’Errico E, Tortelli R, Distaso E, Cortese R, Tursi M, et al. Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS One. 2013;8(11):e80748.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Agosta F, Pagani E, Rocca MA, Caputo D, Perini M, Salvi F, et al. Voxel-based morphometry study of brain volumetry and diffusivity in amyotrophic lateral sclerosis patients with mild disability. Hum Brain Mapp. 2007;28(12):1430–8.

    CAS  PubMed  Google Scholar 

  22. 22.

    Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, Miller BL, et al. A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology. 2005;65(1):75–80.

    CAS  PubMed  Google Scholar 

  23. 23.

    Canu E, Agosta F, Riva N, Sala S, Prelle A, Caputo D, et al. The topography of brain microstructural damage in amyotrophic lateral sclerosis assessed using diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2011;32(7):1307–14.

    CAS  PubMed  Google Scholar 

  24. 24.

    Thivard L, Pradat P-F, Lehéricy S, Lacomblez L, Dormont D, Chiras J, et al. Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: relationships with motor disability. J Neurol Neurosurg Psychiatry. 2007;78(8):889–92.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Schuster C, Kasper E, Machts J, Bittner D, Kaufmann J, Benecke R, et al. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol. 2013;260(11):2856–64.

    PubMed  Google Scholar 

  26. 26.

    Ellis CM, Suckling J, Amaro E, Bullmore ET, Simmons A, Williams SC, et al. Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS. Neurology. 2001;57(9):1571–8.

    CAS  PubMed  Google Scholar 

  27. 27.

    Devine MS, Pannek K, Coulthard A, Mccombe PA, Rose SE, Henderson RD. Exposing asymmetric gray matter vulnerability in amyotrophic lateral sclerosis. NeuroImage Clin. 2015;7:782–7.

    PubMed  PubMed Central  Google Scholar 

  28. 28.

    Zhang Q, Mao C, Jin J, Niu C, Bai L, Dang J, et al. Side of Limb-Onset Predicts Laterality of Gray Matter Loss in Amyotrophic Lateral Sclerosis. BioMed Res Int. 2014;2014:1–11.

    Google Scholar 

  29. 29.

    Walhout R, Westeneng H-J, Verstraete E, Hendrikse J, Veldink JH, van den Heuvel MP, et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry. 2015;86(3):288–94.

    PubMed  Google Scholar 

  30. 30.

    Verstraete E, van den Heuvel MP, Veldink JH, Blanken N, Mandl RC, Hulshoff Pol HE, et al. Motor Network Degeneration in Amyotrophic Lateral Sclerosis: A Structural and Functional Connectivity Study. Zhan W, editor. PLoS ONE. 2010 Oct 27;5(10):e13664.

  31. 31.

    Zhu W, Fu X, Cui F, Yang F, Ren Y, Zhang X, et al. ALFF Value in Right Parahippocampal Gyrus Acts as a Potential Marker Monitoring Amyotrophic Lateral Sclerosis Progression: a Neuropsychological, Voxel-Based Morphometry, and Resting-State Functional MRI Study. J Mol Neurosci [Internet]. 2015 Jun 4 [cited 2015 Jul 29]; Available from: http://link.springer.com/10.1007/s12031-015-0583-9

  32. 32.

    Kassubek J, Unrath A, Huppertz H, Lulé D, Ethofer T, Sperfeld A, et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel‐based morphometry of 3‐D MRI. Amyotroph Lateral Scler. 2005;6(4):213–20.

    Google Scholar 

  33. 33.

    Sach M, Winkler G, Glauche V, Liepert J, Heimbach B, Koch MA, et al. Diffusion tensor MRI of early upper motor neuron involvement in amyotrophic lateral sclerosis. Brain J Neurol. 2004;127(Pt 2):340–50.

    Google Scholar 

  34. 34.

    Sage CA, Peeters RR, Görner A, Robberecht W, Sunaert S. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage. 2007;34(2):486–99.

    PubMed  Google Scholar 

  35. 35.

    Agosta F, Valsasina P, Riva N, Copetti M, Messina MJ, Prelle A, et al. The cortical signature of amyotrophic lateral sclerosis. PLoS One. 2012;7(8):e42816.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Cerami C, Dodich A, Canessa N, Crespi C, Iannaccone S, Corbo M, et al. Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study. Amyotroph Lateral Scler Front Degener. 2014;15(1–2):21–9.

    Google Scholar 

  37. 37.

    Bede P, Bokde ALW, Byrne S, Elamin M, McLaughlin RL, Kenna K, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology. 2013;81(4):361–9.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Westeneng H-J, Verstraete E, Walhout R, Schmidt R, Hendrikse J, Veldink JH, et al. Subcortical structures in amyotrophic lateral sclerosis. Neurobiol Aging [Internet]. 2014 Sep [cited 2014 Nov 6]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0197458014005971

  39. 39.

    Abdulla S, Machts J, Kaufmann J, Patrick K, Kollewe K, Dengler R, et al. Hippocampal degeneration in patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2014;35(11):2639–45.

    PubMed  Google Scholar 

  40. 40.

    Chapman MC, Jelsone-Swain L, Fling BW, Johnson TD, Gruis K, Welsh RC. Corpus callosum area in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(6):589–91.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Meadowcroft MD, Mutic NJ, Bigler DC, Wang J, Simmons Z, Connor JR, et al. Histological-MRI correlation in the primary motor cortex of patients with amyotrophic lateral sclerosis: MRI and Histological Analysis of the PMC in ALS. J Magn Reson Imaging. 2015;41(3):665–75.

    PubMed  Google Scholar 

  42. 42.

    Le Bihan D, Mangin JF, Poupon C, Clark CA, Pappata S, Molko N, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging JMRI. 2001;13(4):534–46.

    PubMed  Google Scholar 

  43. 43.

    Habas C. Basic principles of diffusion tensor MR tractography. J Radiol. 2004;85(3):281–6.

    CAS  PubMed  Google Scholar 

  44. 44.

    Yamada K, Sakai K, Akazawa K, Yuen S, Nishimura T. MR tractography: a review of its clinical applications. Magn Reson Med Sci MRMS Off J Jpn Soc Magn Reson Med. 2009;8(4):165–74.

    Google Scholar 

  45. 45.

    Ciccarelli O, Behrens TE, Johansen-Berg H, Talbot K, Orrell RW, Howard RS, et al. Investigation of white matter pathology in ALS and PLS using tract-based spatial statistics. Hum Brain Mapp. 2009;30(2):615–24.

    PubMed  Google Scholar 

  46. 46.

    Nickerson JP, Koski CJ, Boyer AC, Burbank HN, Tandan R, Filippi CG. Linear longitudinal decline in fractional anisotropy in patients with amyotrophic lateral sclerosis: preliminary results. Klin Neuroradiol. 2009;19(2):129–34.

    PubMed  Google Scholar 

  47. 47.

    Stagg CJ, Knight S, Talbot K, Jenkinson M, Maudsley AA, Turner MR. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology. 2013;80(7):610–5.

    PubMed  PubMed Central  Google Scholar 

  48. 48.

    Yin H, Cheng SHT, Zhang J, Ma L, Gao Y, Li D, et al. Corticospinal tract degeneration in amyotrophic lateral sclerosis: a diffusion tensor imaging and fibre tractography study. Ann Acad Med Singapore. 2008;37(5):411–5.

    PubMed  Google Scholar 

  49. 49.

    Iwata NK, Aoki S, Okabe S, Arai N, Terao Y, Kwak S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology. 2008;70(7):528–32.

    CAS  PubMed  Google Scholar 

  50. 50.

    Iwata NK, Kwan JY, Danielian LE, Butman JA, Tovar-Moll F, Bayat E, et al. White matter alterations differ in primary lateral sclerosis and amyotrophic lateral sclerosis. Brain. 2011;134(9):2642–55.

    PubMed  PubMed Central  Google Scholar 

  51. 51.

    Ellis CM, Simmons A, Jones DK, Bland J, Dawson JM, Horsfield MA, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 1999;53(5):1051–8.

    CAS  PubMed  Google Scholar 

  52. 52.

    Sage CA, Van Hecke W, Peeters R, Sijbers J, Robberecht W, Parizel P, et al. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis: revisited. Hum Brain Mapp. 2009;30(11):3657–75.

    PubMed  Google Scholar 

  53. 53.

    Sarica A, Cerasa A, Vasta R, Perrotta P, Valentino P, Mangone G, et al. Tractography in amyotrophic lateral sclerosis using a novel probabilistic tool: a study with tract-based reconstruction compared to voxel-based approach. J Neurosci Methods. 2014;224:79–87.

    PubMed  Google Scholar 

  54. 54.

    Schimrigk SK, Bellenberg B, Schlüter M, Stieltjes B, Drescher R, Rexilius J, et al. Diffusion tensor imaging-based fractional anisotropy quantification in the corticospinal tract of patients with amyotrophic lateral sclerosis using a probabilistic mixture model. AJNR Am J Neuroradiol. 2007;28(4):724–30.

    CAS  PubMed  Google Scholar 

  55. 55.

    Foerster BR, Carlos RC, Dwamena BA, Callaghan BC, Petrou M, Edden RAE, et al. Multimodal MRI as a diagnostic biomarker for amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2014;1(2):107–14.

    PubMed  PubMed Central  Google Scholar 

  56. 56.

    Filippini N, Douaud G, MacKay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology. 2010;75(18):1645–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Rosskopf J, Müller H-P, Dreyhaupt J, Gorges M, Ludolph AC, Kassubek J. Ex post facto assessment of diffusion tensor imaging metrics from different MRI protocols: Preparing for multicentre studies in ALS. Amyotroph Lateral Scler Front Degener. 2015;9:1–10.

    Google Scholar 

  58. 58.

    Tang M, Chen X, Zhou Q, Liu B, Liu Y, Liu S, et al. Quantitative assessment of amyotrophic lateral sclerosis with diffusion tensor imaging in 3.0 T magnetic resonance. Int J Clin Exp Med. 2015;8(5):8295–303.

    PubMed  PubMed Central  Google Scholar 

  59. 59.

    Pyra T, Hui B, Hanstock C, Concha L, Wong JCT, Beaulieu C, et al. Combined structural and neurochemical evaluation of the corticospinal tract in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1–2):157–65.

    CAS  PubMed  Google Scholar 

  60. 60.

    Prell T, Peschel T, Hartung V, Kaufmann J, Klauschies R, Bodammer N, et al. Diffusion tensor imaging patterns differ in bulbar and limb onset amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2013;115(8):1281–7.

    PubMed  Google Scholar 

  61. 61.

    Keil C, Prell T, Peschel T, Hartung V, Dengler R, Grosskreutz J. Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neurosci. 2012;13(1):141.

    PubMed  PubMed Central  Google Scholar 

  62. 62.

    Zhang Y, Schuff N, Woolley SC, Chiang GC, Boreta L, Laxamana J, et al. Progression of white matter degeneration in amyotrophic lateral sclerosis: A diffusion tensor imaging study. Amyotroph Lateral Scler. 2011;12(6):421–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. 63.

    Rajagopalan V, Allexandre D, Yue GH, Pioro EP. Diffusion Tensor Imaging Evaluation of Corticospinal Tract Hyperintensity in Upper Motor Neuron-Predominant ALS Patients. J Aging Res. 2011;2011:481745.

    PubMed  PubMed Central  Google Scholar 

  64. 64.

    Abe O, Yamada H, Masutani Y, Aoki S, Kunimatsu A, Yamasue H, et al. Amyotrophic lateral sclerosis: diffusion tensor tractography and voxel-based analysis. NMR Biomed. 2004;17(6):411–6.

    PubMed  Google Scholar 

  65. 65.

    Poujois A, Schneider FC, Faillenot I, Camdessanché J-P, Vandenberghe N, Thomas-Antérion C, et al. Brain plasticity in the motor network is correlated with disease progression in amyotrophic lateral sclerosis: Functional Cerebral Reorganization, Disease Progression, and ALS. Hum Brain Mapp. 2013;34(10):2391–401.

    PubMed  Google Scholar 

  66. 66.

    Müller H-P, Lulé D, Unrath A, Ludolph AC, Riecker A, Kassubek J. Complementary image analysis of diffusion tensor imaging and 3-dimensional t1-weighted imaging: white matter analysis in amyotrophic lateral sclerosis. J Neuroimaging Off J Am Soc Neuroimaging. 2011;21(1):24–33.

    Google Scholar 

  67. 67.

    Chapman MC, Jelsone-Swain L, Johnson TD, Gruis KL, Welsh RC. Diffusion tensor MRI of the corpus callosum in amyotrophic lateral sclerosis: DTI of the Corpus Callosum in ALS. J Magn Reson Imaging. 2014;39(3):641–7.

    PubMed  Google Scholar 

  68. 68.

    Keller J, Vymazal J, Ridzoň P, Rusina R, Kulišt’ák P, Malíková H, et al. Quantitative brain MR imaging in amyotrophic lateral sclerosis. Magma N Y N. 2011;24(2):67–76.

    Google Scholar 

  69. 69.

    Metwalli NS, Benatar M, Nair G, Usher S, Hu X, Carew JD. Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis. Brain Res. 2010;1348:156–64.

    CAS  PubMed  Google Scholar 

  70. 70.

    Prudlo J, Bißbort C, Glass A, Grossmann A, Hauenstein K, Benecke R, et al. White matter pathology in ALS and lower motor neuron ALS variants: a diffusion tensor imaging study using tract-based spatial statistics. J Neurol. 2012;259(9):1848–59.

    PubMed  Google Scholar 

  71. 71.

    Wang S, Poptani H, Bilello M, Wu X, Woo JH, Elman LB, et al. Diffusion tensor imaging in amyotrophic lateral sclerosis: volumetric analysis of the corticospinal tract. Am J Neuroradiol. 2006;27(6):1234–8.

    CAS  PubMed  Google Scholar 

  72. 72.

    Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis: ALS Stages. Ann Neurol. 2013;74(1):20–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Kassubek J, Muller H-P, Del Tredici K, Brettschneider J, Pinkhardt EH, Lule D, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain. 2014;137(6):1733–40.

    PubMed  Google Scholar 

  74. 74.

    Ding X-Q, Kollewe K, Blum K, Körner S, Kehbel S, Dengler R, et al. Value of quantitative analysis of routine clinical MRI sequences in ALS. Amyotroph Lateral Scler. 2011;12(6):406–13.

    PubMed  Google Scholar 

  75. 75.

    Bede P, Elamin M, Byrne S, McLaughlin RL, Kenna K, Vajda A, et al. Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosurg Psychiatry. 2015;86(4):468–70.

    CAS  PubMed  Google Scholar 

  76. 76.

    Jacob S, Finsterbusch J, Weishaupt JH, Khorram-Sefat D, Frahm J, Ehrenreich H. Diffusion tensor imaging for long-term follow-up of corticospinal tract degeneration in amyotrophic lateral sclerosis. Neuroradiology. 2003;45(9):598–600.

    CAS  PubMed  Google Scholar 

  77. 77.

    Menke RAL, Abraham I, Thiel CS, Filippini N, Knight S, Talbot K, et al. Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Arch Neurol. 2012;69(11):1493.

    PubMed  Google Scholar 

  78. 78.

    Menke RAL, Korner S, Filippini N, Douaud G, Knight S, Talbot K, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain. 2014;137(9):2546–55.

    PubMed  PubMed Central  Google Scholar 

  79. 79.

    Lombardo F, Frijia F, Bongioanni P, Canapicchi R, Minichilli F, Bianchi F, et al. Diffusion tensor MRI and MR spectroscopy in long lasting upper motor neuron involvement in amyotrophic lateral sclerosis. Arch Ital Biol. 2009;147(3):69–82.

    CAS  PubMed  Google Scholar 

  80. 80.

    Cardenas-Blanco A, Machts J, Acosta-Cabronero J, Kaufmann J, Abdulla S, Kollewe K, et al. Central white matter degeneration in bulbar- and limb-onset amyotrophic lateral sclerosis. J Neurol. 2014;261(10):1961–7.

    PubMed  Google Scholar 

  81. 81.

    Foerster BR, Dwamena BA, Petrou M, Carlos RC, Callaghan BC, Churchill CL, et al. Diagnostic accuracy of diffusion tensor imaging in amyotrophic lateral sclerosis: a systematic review and individual patient data meta-analysis. Acad Radiol. 2013;20(9):1099–106.

    PubMed  PubMed Central  Google Scholar 

  82. 82.

    Galanaud D, Nicoli F, Confort-Gouny S, Le Fur Y, Dormont D, Girard N, et al. Brain magnetic resonance spectroscopy. J Radiol. 2007;88(3 Pt 2):483–96.

    CAS  PubMed  Google Scholar 

  83. 83.

    Jissendi Tchofo P, Balériaux D. Brain (1)H-MR spectroscopy in clinical neuroimaging at 3T. J Neuroradiol. 2009;36(1):24–40.

    CAS  PubMed  Google Scholar 

  84. 84.

    Soares DP, Law M. Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol. 2009;64(1):12–21.

    CAS  PubMed  Google Scholar 

  85. 85.

    Han J, Ma L. Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis. J Magn Reson Imaging JMRI. 2010;31(2):305–8.

    PubMed  Google Scholar 

  86. 86.

    Rooney WD, Miller RG, Gelinas D, Schuff N, Maudsley AA, Weiner MW. Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology. 1998;50(6):1800–5.

    CAS  PubMed  Google Scholar 

  87. 87.

    Liu C, Jiang R, Yi X, Zhu W, Bu B. Role of diffusion tensor imaging or magnetic resonance spectroscopy in the diagnosis and disability assessment of amyotrophic lateral sclerosis. J Neurol Sci. 2015;348(1–2):206–10.

    PubMed  Google Scholar 

  88. 88.

    Kalra S, Vitale A, Cashman NR, Genge A, Arnold DL. Cerebral degeneration predicts survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(11):1253–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Kalra S, Hanstock CC, Martin WW, Allen PS, Johnston WS. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch Neurol. 2006;63(8):1144–8.

    PubMed  Google Scholar 

  90. 90.

    Cervo A, Cocozza S, Saccà F, Giorgio SMDA, Morra VB, Tedeschi E, et al. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. Eur J Radiol. 2015;84(1):151–7.

    PubMed  Google Scholar 

  91. 91.

    Pohl C, Block W, Träber F, Schmidt S, Pels H, Grothe C, et al. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci. 2001;190(1–2):21–7.

    CAS  PubMed  Google Scholar 

  92. 92.

    Govind V, Sharma KR, Maudsley AA, Arheart KL, Saigal G, Sheriff S. Comprehensive evaluation of corticospinal tract metabolites in amyotrophic lateral sclerosis using whole-brain 1H MR spectroscopy. PLoS One. 2012;7(4):e35607.

    CAS  PubMed  PubMed Central  Google Scholar 

  93. 93.

    Verma G, Woo JH, Chawla S, Wang S, Sheriff S, Elman LB, et al. Whole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging. Radiology. 2013;267(3):851–7.

    PubMed  PubMed Central  Google Scholar 

  94. 94.

    Bowen BC, Pattany PM, Bradley WG, Murdoch JB, Rotta F, Younis AA, et al. MR imaging and localized proton spectroscopy of the precentral gyrus in amyotrophic lateral sclerosis. Am J Neuroradiol. 2000;21(4):647–58.

    CAS  PubMed  Google Scholar 

  95. 95.

    Foerster BR, Callaghan BC, Petrou M, Edden RAE, Chenevert TL, Feldman EL. Decreased motor cortex γ-aminobutyric acid in amyotrophic lateral sclerosis. Neurology. 2012;78(20):1596–600.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Unrath A, Ludolph AC, Kassubek J. Brain metabolites in definite amyotrophic lateral sclerosis: A longitudinal proton magnetic resonance spectroscopy study. J Neurol. 2007;254(8):1099–106.

    CAS  PubMed  Google Scholar 

  97. 97.

    Wang Q, Zhang X, Chen S, Zhang X, Zhang S, Youdium M, et al. Prevention of Motor Neuron Degeneration by Novel Iron Chelators in SOD1(G93A) Transgenic Mice of Amyotrophic Lateral Sclerosis. Neurodegener Dis. 2011;8(5):310–21.

    CAS  PubMed  Google Scholar 

  98. 98.

    Deistung A, Schäfer A, Schweser F, Biedermann U, Turner R, Reichenbach JR. Toward in vivo histology: A comparison of quantitative susceptibility mapping (QSM) with magnitude-, phase-, and R2*-imaging at ultra-high magnetic field strength. Neuroimage. 2013;65:299–314.

    PubMed  Google Scholar 

  99. 99.

    Haacke EM, Cheng NYC, House MJ, Liu Q, Neelavalli J, Ogg RJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging. 2005;23(1):1–25.

    CAS  PubMed  Google Scholar 

  100. 100.

    Adachi Y, Sato N, Saito Y, Kimura Y, Nakata Y, Ito K, et al. Usefulness of SWI for the Detection of Iron in the Motor Cortex in Amyotrophic Lateral Sclerosis: Usefulness of SWI for the Diagnoses of ALS. J Neuroimaging. 2015;25(3):443–51.

    PubMed  Google Scholar 

  101. 101.

    Chavhan GB, Babyn PS, Thomas B, Shroff MM, Haacke EM. Principles, Techniques, and Applications of T2*-based MR Imaging and Its Special Applications1. RadioGraphics. 2009;29(5):1433–49.

    PubMed  PubMed Central  Google Scholar 

  102. 102.

    Haacke EM, Miao Y, Liu M, Habib CA, Katkuri Y, Liu T, et al. Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults. J Magn Reson Imaging JMRI. 2010;32(3):561–76.

    PubMed  Google Scholar 

  103. 103.

    Langkammer C, Krebs N, Goessler W, Scheurer E, Ebner F, Yen K, et al. Quantitative MR imaging of brain iron: a postmortem validation study. Radiology. 2010;257(2):455–62.

    PubMed  Google Scholar 

  104. 104.

    Haacke EM, Liu S, Buch S, Zheng W, Wu D, Ye Y. Quantitative susceptibility mapping: current status and future directions. Magn Reson Imaging. 2015;33(1):1–25.

    PubMed  Google Scholar 

  105. 105.

    Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, et al. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. Neuroimage. 2012;62(3):1593–9.

    PubMed  PubMed Central  Google Scholar 

  106. 106.

    Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993;189(3):843–6.

    CAS  PubMed  Google Scholar 

  107. 107.

    Hecht MJ, Fellner C, Schmid A, Neundörfer B, Fellner FA. Cortical T2 signal shortening in amyotrophic lateral sclerosis is not due to iron deposits. Neuroradiology. 2005;47(11):805–8.

    CAS  PubMed  Google Scholar 

  108. 108.

    Ignjatović A, Stević Z, Lavrnić S, Daković M, Bačić G. Brain iron MRI: A biomarker for amyotrophic lateral sclerosis: Brain Iron MRI: A Biomarker for ALS. J Magn Reson Imaging. 2013;38(6):1472–9.

    PubMed  Google Scholar 

  109. 109.

    Yu J, Qi F, Wang N, Gao P, Dai S, Lu Y, et al. Increased iron level in motor cortex of amyotrophic lateral sclerosis patients: An in vivo MR study. Amyotroph Lateral Scler Front Degener. 2014;15(5–6):357–61.

    CAS  Google Scholar 

  110. 110.

    Langkammer C, Enzinger C, Quasthoff S, Grafenauer P, Soellinger M, Fazekas F, et al. Mapping of iron deposition in conjunction with assessment of nerve fiber tract integrity in amyotrophic lateral sclerosis. J Magn Reson Imaging JMRI. 2010;31(6):1339–45.

    PubMed  Google Scholar 

  111. 111.

    Prell T, Hartung V, Tietz F, Penzlin S, Ilse B, Schweser F, et al. Susceptibility-Weighted Imaging Provides Insight into White Matter Damage in Amyotrophic Lateral Sclerosis. Kassubek J, editor. PLOS ONE. 2015 Jun 25;10(6):e0131114.

  112. 112.

    Schweitzer AD, Liu T, Gupta A, Zheng K, Seedial S, Shtilbans A, et al. Quantitative Susceptibility Mapping of the Motor Cortex in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis. Am J Roentgenol. 2015;204(5):1086–92.

    Google Scholar 

  113. 113.

    Branco LMT, De Albuquerque M, De Andrade HMT, Bergo FPG, Nucci A, França MC. Spinal cord atrophy correlates with disease duration and severity in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15(1–2):93–7.

    Google Scholar 

  114. 114.

    Cohen-Adad J, Mendili M-ME, Morizot-Koutlidis R, Lehéricy S, Meininger V, Blancho S, et al. Involvement of spinal sensory pathway in ALS and specificity of cord atrophy to lower motor neuron degeneration. Amyotroph Lateral Scler Front Degener. 2013;14(1):30–8.

    Google Scholar 

  115. 115.

    El Mendili M-M, Cohen-Adad J, Pelegrini-Issac M, Rossignol S, Morizot-Koutlidis R, Marchand-Pauvert V, et al. Multi-parametric spinal cord MRI as potential progression marker in amyotrophic lateral sclerosis. PLoS One. 2014;9(4):e95516.

    PubMed  PubMed Central  Google Scholar 

  116. 116.

    Iglesias C, Sangari S, El Mendili M-M, Benali H, Marchand-Pauvert V, Pradat P-F. Electrophysiological and spinal imaging evidences for sensory dysfunction in amyotrophic lateral sclerosis. BMJ Open. 2015;5(2):e007659.

    PubMed  PubMed Central  Google Scholar 

  117. 117.

    Ikeda K, Murata K, Kawase Y, Kawabe K, Kano O, Yoshii Y, et al. Relationship between cervical cord 1H-magnetic resonance spectroscopy and clinoco-electromyographic profile in amyotrophic lateral sclerosis. Muscle Nerve. 2013;47(1):61–7.

    CAS  PubMed  Google Scholar 

  118. 118.

    Barkhof F, Haller S, Rombouts SARB. Resting-state functional MR imaging: a new window to the brain. Radiology. 2014;272(1):29–49.

    PubMed  Google Scholar 

  119. 119.

    Habas C. Physiological basis of functional MRI. J Radiol. 2002;83(11):1737–41.

    CAS  PubMed  Google Scholar 

  120. 120.

    Delmaire C, Krainik A, Lethuc V, Reyns N, Duffau H, Capelle L, et al. Functional magnetic resonance imaging: physiopathology, techniques and applications. J Radiol. 2007;88(3 Pt 2):497–509.

    CAS  PubMed  Google Scholar 

  121. 121.

    Gore JC. Principles and practice of functional MRI of the human brain. J Clin Invest. 2003;112(1):4–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  122. 122.

    Raichle ME. The Restless Brain. Brain Connect. 2011;1(1):3–12.

    PubMed  PubMed Central  Google Scholar 

  123. 123.

    Agosta F, Canu E, Valsasina P, Riva N, Prelle A, Comi G, et al. Divergent brain network connectivity in amyotrophic lateral sclerosis. Neurobiol Aging. 2013;34(2):419–27.

    PubMed  Google Scholar 

  124. 124.

    Jelsone-Swain LM, Fling BW, Seidler RD, Hovatter R, Gruis K, Welsh RC. Reduced Interhemispheric Functional Connectivity in the Motor Cortex during Rest in Limb-Onset Amyotrophic Lateral Sclerosis. Front Syst Neurosci [Internet]. 2010 [cited 2015 Jul 15];4. Available from: http://journal.frontiersin.org/article/10.3389/fnsys.2010.00158/abstract

  125. 125.

    Agosta F, Valsasina P, Absinta M, Riva N, Sala S, Prelle A, et al. Sensorimotor Functional Connectivity Changes in Amyotrophic Lateral Sclerosis. Cereb Cortex. 2011;21(10):2291–8.

    CAS  PubMed  Google Scholar 

  126. 126.

    Mohammadi B, Kollewe K, Samii A, Krampfl K, Dengler R, Münte TF. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol. 2009;217(1):147–53.

    PubMed  Google Scholar 

  127. 127.

    Douaud G, Filippini N, Knight S, Talbot K, Turner MR. Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis. Brain. 2011;134(12):3470–9.

    PubMed  Google Scholar 

  128. 128.

    Luo C, Chen Q, Huang R, Chen X, Chen K, Huang X, et al. Patterns of Spontaneous Brain Activity in Amyotrophic Lateral Sclerosis: A Resting-State fMRI Study. Duce JA, editor. PLoS ONE. 2012 Sep 20;7(9):e45470.

  129. 129.

    Mohammadi B, Kollewe K, Samii A, Dengler R, Münte TF. Functional neuroimaging at different disease stages reveals distinct phases of neuroplastic changes in amyotrophic lateral sclerosis. Hum Brain Mapp. 2011;32(5):750–8.

    PubMed  Google Scholar 

  130. 130.

    Mohammadi B, Kollewe K, Cole DM, Fellbrich A, Heldmann M, Samii A, et al. Amyotrophic lateral sclerosis affects cortical and subcortical activity underlying motor inhibition and action monitoring: ALS and Motor Inhibition. Hum Brain Mapp. 2015;36(8):2878–89.

    PubMed  Google Scholar 

  131. 131.

    Kollewe K, Münte TF, Samii A, Dengler R, Petri S, Mohammadi B. Patterns of cortical activity differ in ALS patients with limb and/or bulbar involvement depending on motor tasks. J Neurol. 2011;258(5):804–10.

    PubMed  Google Scholar 

  132. 132.

    Konrad C, Henningsen H, Bremer J, Mock B, Deppe M, Buchinger C, et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res. 2002;143(1):51–6.

    PubMed  Google Scholar 

  133. 133.

    Schoenfeld MA, Tempelmann C, Gaul C, Kühnel GR, Düzel E, Hopf J-M, et al. Functional motor compensation in amyotrophic lateral sclerosis. J Neurol. 2005;252(8):944–52.

    PubMed  Google Scholar 

  134. 134.

    Lule D, Diekmann V, Muller H-P, Kassubek J, Ludolph AC, Birbaumer N. Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(8):899–906.

    PubMed  Google Scholar 

  135. 135.

    Stoppel CM, Vielhaber S, Eckart C, Machts J, Kaufmann J, Heinze H-J, et al. Structural and functional hallmarks of amyotrophic lateral sclerosis progression in motor- and memory-related brain regions. NeuroImage Clin. 2014;5:277–90.

    PubMed  PubMed Central  Google Scholar 

  136. 136.

    Jelsone-Swain L, Persad C, Burkard D, Welsh RC. Action Processing and Mirror Neuron Function in Patients with Amyotrophic Lateral Sclerosis: An fMRI Study. Iacoboni M, editor. PLOS ONE. 2015 Apr 17;10(4):e0119862.

  137. 137.

    Bede P, Hardiman O. Lessons of ALS imaging: Pitfalls and future directions - A critical review. NeuroImage Clin. 2014;4:436–43.

    PubMed  PubMed Central  Google Scholar 

  138. 138.

    Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Mot Neuron Disord Off Publ World Fed Neurol Res Group Mot Neuron Dis. 2000;1(5):293–9.

    CAS  Google Scholar 

  139. 139.

    Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12(12):921–38.

    CAS  PubMed  Google Scholar 

  140. 140.

    Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009;8(1):94–109.

    CAS  PubMed  Google Scholar 

  141. 141.

    Pradat P-F, Bruneteau G. [Clinical characteristics of amyotrophic lateral sclerosis subsets]. Rev Neurol (Paris). 2006 Jun;162 Spec No 2:4S29-24S33.

  142. 142.

    Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci. 2006;250(1–2):45–9.

    PubMed  Google Scholar 

  143. 143.

    Pradat P-F, El Mendili M-M. Neuroimaging to investigate multisystem involvement and provide biomarkers in amyotrophic lateral sclerosis. BioMed Res Int. 2014;2014:467560.

    PubMed  PubMed Central  Google Scholar 

  144. 144.

    Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(5):400–3.

    PubMed  Google Scholar 

  145. 145.

    Filippi M, Agosta F, Grosskreutz J, Benatar M, Kassubek J, Verstraete E, et al. Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 2015;14(8):786–8.

    PubMed  Google Scholar 

  146. 146.

    Müller H-P, Turner MR, Grosskreutz J, Abrahams S, Bede P, Govind V, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(6):570–9.

    PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. David Fraser (Biotech Communication, Damery, France) for editing the article.

Funding

Not applicable.

Availability of data and materials

Data and the findings are fully available without restriction upon request to the authors.

Authors’ contribution

GG, CM, VDB, CD, LD and DD: conception of the study. GG and DD: writing the first draft and the final draft. CM, VDB, CD, RL, PFP, MMEM and LD: review and critical coment. All authors have read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests about this manuscript.

Consent for publication

Not applicable as this manuscript is a systematic review and not a clinical trial.

Ethics approval and consent to participate

Not applicable as this manuscript is a systematic review and not a clinical trial.

Author information

Affiliations

Authors

Corresponding author

Correspondence to D. Devos.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Grolez, G., Moreau, C., Danel-Brunaud, V. et al. The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol 16, 155 (2016). https://doi.org/10.1186/s12883-016-0672-6

Download citation

Keywords

  • Amyotrophic lateral sclerosis
  • Magnetic resonance imaging
  • Morphometry
  • Diffusion tensor imaging
  • Magnetic resonance spectroscopy
  • Spinal cord
  • Biomarkers